A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia (EMBOSSES)

Novartis

Status: Completed

Conditions: Secondary Progressive Multiple Sclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT07168694

CBAF312ARU02

Details and patient eligibility

About

The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.

Enrollment: 606 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of SPMS, with or without relapses.
• Treatment with siponimod for at least 6 months.

Exclusion criteria

None.

Trial design

606 participants in 1 patient group

Siponimod Cohort

Description:

Adult patients with SPMS who were treated with siponimod.